Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05207722
Title CYNK-101 in Combination With Trastuzumab and Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Celularity Incorporated
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Scripps Health La Jolla California 92037 United States Details
Georgetown Washington District of Columbia 20057 United States Details
John Theurer Cancer Center at Hackensack University Medical Center Hackensack New Jersey 07601 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field